Zydus in deal with Pieris for novel Anticalin therapeutics

Indian drugmaker Zydus Cadila has entered into an alliance with privately-held German company Pieris AG for development and commercialization of multiple novel Anticalin-based protein therapeutics.

The collaboration combines Pieris’ drug discovery and early development capabilities with Zydus’ expertise in biologics development, regulatory affairs and biologics manufacturing. Under the terms of the agreement, Zydus will take the lead in advancing Anticalin drug candidates through formal preclinical development and into clinical development, undertaking drug development in accordance with ICH guidelines.

Zydus has been granted exclusive marketing rights in India and several other emerging markets, while Pieris retains exclusive marketing rights in key developed markets. Financial terms of the agreement were not disclosed.